COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from COV005: a phase 1b/2, multicenter, double-blind, randomized, placebo-controlled study of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination in South African adults aged 18-65 years. South Africa's first, second, and third waves of infection were dominated by the wild type (WT), Beta, and Delta variants, respectively.
Publisher
Vaccine
Published On
Apr 26, 2023
Authors
Anthonet L Koen, Alane Izu, Vicky Baillie, Gaurav Kwatra, Clare L Cutland, Lee Fairlie, Sherman D Padayachee, Keertan Dheda, Shaun L Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Khatija Ahmed, Sutika Bhikha, Jinal N Bhiman, Jeanine Du Plessis, Aliasgar Esmail, Elizea Horne, Shi-Hsia Hwa, Aylin Oommen-Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Gabriella Benade, Shakeel Mckenzie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Tonya L Villafana, Sarah Gilbert, Andrew J Pollard, Shabir A Madhi
Tags
COVID-19
vaccine efficacy
SARS-CoV-2
variants of concern
AZD1222
safety
clinical trial
Related Publications
Explore these studies to deepen your understanding of the subject.
